The biosurgery market is a highly competitive market, with large number of players competing for greater market penetrance and higher market shares. Some of the major players in this market include Johnson & Johnson (U.S.), Baxter International Inc. (U.S.), Sanofi Group (France), Covidien plc (Ireland), Cryolife, Inc. (U.S.), Stryker Corporation (U.S.), and Getinge Group (Sweden).
Johnson & Johnson (U.S.) led the sealants, hemostatic agents, adhesion barriers, and staple-line reinforcement agents market in 2014. This was majorly attributed to the company’s strong and wide product portfolio and strong presence across the globe, covering North America, Europe, the Middle East and Africa, and Asia-Pacific. The company strongly focuses on introducing new products and gaining regulatory approvals for its products in different markets. The company gained approvals for additional indications for its existing products which strengthened its revenue generation. Moreover, in May 2011, the company launched a new product—ETHICON SECURESTRAP 5mm Absorbable Strap in the U.S., which widened its portfolio for the biosurgery market. Baxter International, Inc. (U.S.) was the second leading company for the sealants, hemostatic agents, adhesion barriers, and staple-line reinforcement agents market in 2014.
Medtronic, Inc. (U.S.) led the bone-graft substitutes market in 2014 owing to its strong product portfolio and significant presence in the demineralized bone matrix (DBM) market. The other leading players in the bone-graft substitute products market include Johnson & Johnson (U.S.), Integra LifeSciences (U.S.), and Stryker Corporation (U.S.).
Mergers and acquisitions, expansions, and new product launches were the key strategies adopted by major players in the biosurgery market from 2011 to 2015. Mergers and acquisitions was the preferred growth strategy during the forecast period, as this strategy enabled greater penetrance of the market through better product offerings.